Inventiva's 2025 Q3 Financial Update

Inventiva, a biopharmaceutical firm, disclosed its financial status as of September 30, 2025. The company reported cash and cash equivalents totaling €97.6 million, supplemented by €24.7 million in short-term deposits.

For the first nine months of 2025, Inventiva recorded revenues of €4.5 million, marking a significant change from the absence of revenues in the same period in 2024. These earnings primarily stem from a milestone payment and credit notes with Chia Tai Tianqing Pharmaceutical Group.

The company's operational expenses rose, with net cash used in operating activities increasing by 20% to (€76.3) million. Despite this, decreased R&D expenses slightly offset the rise. Financing activities generated €103.4 million owing to structured financing tranches.

Inventiva foresees its cash operations extending to the end of Q1 2027, with potential extension to mid-Q3 2027 depending on further financing actions.